Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model
Related Experiment Video
Updated: Jul 4, 2026

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Nico Marr1, David C Oliver, Vincianne Laurent
1Department of Microbiology and Immunology, University of British Columbia, 2350 Health Sciences Mall, Vancouver, BC, Canada V6T 1Z3.
Abstract:
This study examined the vaccine potential of the autotransporter protein BrkA of Bordetella pertussis in the sublethal intranasal murine respiratory challenge model of infection. Five different acellular pertussis (Pa) vaccines, containing different pertussis-component antigens but all comprizing diphtheria (D) and tetanus (T) toxoids, were tested. A two-pertussis-component DTPa vaccine containing pertussis toxoid (PT) and filamentous hemagglutinin (FHA) induced only limited bacterial clearance. However, a three-pertussis-component DTPa vaccine containing PT, FHA and a recombinant BrkA protein (rBrkA) was found to be as efficacious in protecting mice against colonization by B. pertussis strains Tohama I and 18-323 as the commercial Infanrixtrade mark vaccine that also includes PT and FHA but pertactin (PRN) instead of rBrkA. Vaccination of mice with rBrkA as the only B. pertussis antigen did not protect against colonization by B. pertussis. We also demonstrated that BrkA is ubiquitously expressed by highly prevalent clinical isolates of B. pertussis and suggest that new acellular pertussis vaccine formulations that include BrkA have equivalent efficacy as currently available DTPa vaccines against B. pertussis infections.
More Related Videos
06:43Studying Microbial Communities In Vivo: A Model of Host-mediated Interaction Between Candida Albicans and Pseudomonas Aeruginosa in the Airways
Published on: January 13, 2016
06:32Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016